Summit Trail Advisors LLC Raises Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Summit Trail Advisors LLC boosted its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 9.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,964 shares of the company’s stock after purchasing an additional 352 shares during the period. Summit Trail Advisors LLC’s holdings in HCA Healthcare were worth $1,190,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HCA. FMR LLC raised its stake in shares of HCA Healthcare by 322.3% in the 3rd quarter. FMR LLC now owns 3,141,769 shares of the company’s stock valued at $1,276,909,000 after acquiring an additional 2,397,883 shares during the period. Meritage Group LP purchased a new stake in shares of HCA Healthcare in the 3rd quarter valued at approximately $150,548,000. Canoe Financial LP raised its stake in shares of HCA Healthcare by 226,952.9% in the 4th quarter. Canoe Financial LP now owns 231,594 shares of the company’s stock valued at $69,513,000 after acquiring an additional 231,492 shares during the period. Holocene Advisors LP increased its stake in HCA Healthcare by 210.6% during the 3rd quarter. Holocene Advisors LP now owns 306,796 shares of the company’s stock worth $124,691,000 after buying an additional 208,015 shares during the period. Finally, Nordea Investment Management AB increased its stake in HCA Healthcare by 29.7% during the 4th quarter. Nordea Investment Management AB now owns 843,764 shares of the company’s stock worth $253,020,000 after buying an additional 193,075 shares during the period. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Trading Up 1.7 %

Shares of HCA Healthcare stock opened at $323.71 on Wednesday. The company has a fifty day simple moving average of $313.56 and a 200-day simple moving average of $353.26. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14. The stock has a market cap of $81.99 billion, a price-to-earnings ratio of 14.73, a PEG ratio of 1.11 and a beta of 1.64. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same period in the prior year, the business posted $5.90 earnings per share. On average, equities analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be given a dividend of $0.72 per share. The ex-dividend date is Monday, March 17th. This represents a $2.88 dividend on an annualized basis and a yield of 0.89%. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.66. HCA Healthcare’s dividend payout ratio is presently 12.02%.

Analysts Set New Price Targets

Several brokerages recently weighed in on HCA. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 target price on shares of HCA Healthcare in a research note on Monday, January 27th. KeyCorp cut their target price on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 7th. Truist Financial lowered their price target on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a report on Monday, January 6th. Royal Bank of Canada lowered their price target on shares of HCA Healthcare from $405.00 to $384.00 and set an “outperform” rating for the company in a report on Monday, January 27th. Finally, Raymond James cut shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $385.67.

Insiders Place Their Bets

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the transaction, the insider now owns 6,843 shares in the company, valued at approximately $2,415,579. This represents a 29.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Phillip G. Billington sold 3,897 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the transaction, the senior vice president now owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.